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Abstract
Drug related problem (DRPs) is a key factor which will affect the outcome of  therapy and safety. The aim of  the present 
study is to assess the DRPs in T2DM patients and psychological aspects of  patients by community pharmacists to observe 
the rate of  DRP. Prospective randomized controlled intervention study involved T2DM patients and conducted in two 
community pharmacies at Kanpur from January 2012 to December 2012. The assessment of  DRPs was based on the 
PCNE. Changes in HBA1C, LDL, BP, foot examinations, changes medical and medication utilization were studied. Using as 
control group, received usual care, and interventional group provided, intervened with use of  the STG. Researcher provided 
the knowledge to community pharmacists and patients. Baseline and interventional data were collected at 0,3,6,9 and 12 
months. Over 12 month study, participants’ average HBA1C reduced from 8.9% at initial visit to 7.5%. During this time, 
the eye examination rate was raised from 31% to 48%, and the foot examination rate was raised from 35% to 50%. It may 
be concluded that the intervention of  pharmacists showed very less significant influence on any of  the intermediate health 
outcomes in T2DM.




The type 2 diabetes mellitus (T2DM) is a chronic 
metabolic disorder characterised by defects in insulin 
secretion and/or insulin resistance. It forms part of  a 
cluster of  cardiovascular risk factors seen in at higher 
rates in patients with  T2DM, which is characterised as 
the metabolic syndrome. That includes central obesity, 
hypertension and/or dyslipidaemia etc. (Carrera Boada. 
CA and Martínez-Moreno. JM, 2013) India is the 
leading country in the world with the greatest number 
of  diabetes patients. According to the International 
Diabetes Federation (IDF) atlas 2012, the cases recorded 
for T2DM were 63,013.87 (in 1000s), diabetic related 
deaths constituted for 1,013,057 and undiagnosedcases 
of  T2DM were 32,184.34 (in 1000s). (Whiting. DR et al 
2011 and Anjana RM et al 2011) Hypertension is the
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most common co morbidity in T2DM patients, with a 
prevalence rate up to two-thirds of  the global population. 
Hypertension triggers the risk of  cardiovascular disease 
in T2DM patients and also enhances the possibility of  
developing microvascular complications such as diabetic 
nephropathy and retinopathy. (Paul P. Dobesh, 2006)
 
Patients with any illness or disease along with another 
precipitating co-morbidity condition often receive 
multiple medications which often lead to the occurrence 
of  drug-related problems (DRPs). (Zaman Huri and Fun 
Wee, 2013) A  DRP is an event or circumstance involving 
drug therapy that actually or potentially interferes with 
desired health outcomes. There is a high prevalence rate 
of  DRPs that has been observed in T2DM patients. 
DRPs may lead to additional complications that may 
lead to significant morbidity or mortality, prolonged 
hospitalization, and increased health care expenditure. 
Several problems and causes of  DRPs in T2DM 
patients with hypertension and factors influencing will 
be reported in the study. (Rashed. AN et al, 2012 and) 
To date, polypharmacy (≥5 concurrent medications), 
age status (≥ 65 years old), multiple medical conditions 
and renal impairment have been shown to be the most 
causing influencing factors.     
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Drug-related problems affect the outcomes on 
morbidity, mortality and cost which constitute a major 
public health problem. Most people with diabetes live in 
low- and middle-income countries like India, and these 
countries will also see the greatest increase over the 
next 19 years. The recently published ICMR-INDIAB 
national study reported that there are 62.4 million people 
with T2DM and 77 million people with pre-diabetes in 
India. These numbers are projected to increase to 101 
million by the year 2030. (Whiting DR et  al, 2011 and 
and Anjana RM, et al, 2011) The prevalence of  diabetic 
retinopathy was 17.6%, microalbuminuria in 26.9% 
neuropathy was 26.1%, coronary artery disease (CAD) 
was 21.4% and peripheral vascular disease was 6.3%. (V. 
Mohan et al, 2013).
Objective
The objective of  this study is to assess causes and 
factors of  DRPs in T2DM patients with any comorbid 
conditions so as to enhance therapeutic outcome 
by implementing effective medication review and 
psychological aspects in the treatment plan. 
Methods
Study Design 
The study was designed as a prospective randomized 
controlled intervention involving 723 participants 
with a followup of  one year. The intervention was 
performed by trained community pharmacists with 
the help of  researchers. The Independent Human 
Ethics Committee in Ahmedabad (Approval No.: 
IRB00005741), India has approved the present study 
design, protocols, information letters and informed 
consent form.
Study Setup
The trial was conducted in 2 community pharmacies 
at Kanpur, Uttar Pradesh, India [Anna Hajare 
Medical Clinic and Anjali Hospital & Nursing Home, 
Kanpur.]. The present study was performed by 8 
trained pharmacists in association with diabetologist. 
The patients were counseled in the both pharmacies 
randomly by the trained community pharmacists.
Study Population
723 participants were enrolled into the study those 
regularly visit in the both pharmacies. Participants 
were between 20 and 75 years of  age, the prescriptions 
which contain antidiabetic agent(s) prescribed from 
the TNSTG were only considered as eligible to 
participate in the study. The researcher was identified 
the prescription and obtained written informed consent 
from participants before study starts.
    Inclusion criteria
Patients with diagnosis of  T2DM for > 1 1. 
year prior to entry in the study willing and 
able to complete the questionnaire and on 
pharmacotherapy
Patients who are currently treated with a single 2. 
or combination of  injectable/oral antidiabetic 
drugs with or without insulin therapy
Treatment type must be unchanged in the 3. 
previous 3 months. However, dose modifications 
are allowed
Patients who agree to participate in the study 4. 
and give their written informed consent
Patients aged between above 20 and below 75 5. 
years old.
Exclusion criteria
Patients with type 1 diabetes.1. 
Patients with diabetic ketoacidosis and/or 2. 
hyperosmolar hyperglycaemic state.
Patients with secondary diabetes, including disease 3. 
of  the exocrine pancreas, endocrinopathies.
Patients with concurrent treatment involving 4. 
systemic glucocorticoids. However, inhaled, 
locally injected and topical use of  glucocorticoids 
is allowed.
Patients suffering from severe cardiac, hepatic, 5. 
renal diseases as judged by the investigator.
Any condition of  the patient which may have 6. 
an impact on objective and outcome of  the trial 
example: patients currently undergoing major/ 
minor surgical
Data collection
Demographic characteristics such as age, gender, 
education level, income, height, weight, and body mass 
index were recorded. Clinical characteristics such as 
duration of  hospital stay, duration of  T2DM, presence 
and duration of  comorbidities and presence of  diabetic 
complications. Laboratory results and concurrent 
medications were also collected.
Study procedures
Medication review 
In the intervention group medications of  patients were 
reviewed by the trained community pharmacists by 
utilizing their prescription and the patient’s medication 
evaluation profile. When prescribed by a medical 
specialist, details about the indication for the drug will     
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be obtained from BNF (British National Formulary, 
2010) and TNSTG (Standard Treatment Guidelines, 
2010),. Participants were motivated to adhere for their 
therapy regimen though motivational interviews.
The authors identified and classified the DRPs by 
using PCNE. (PCNE Classification scheme for Drug 
related problems V5.01); PCNE is a recognized, which 
has been reviewed for several times and tested for its 
validity and reproducibility. In the present study, PCNE 
was classified for DRPs as 6 domains and utilized in 
identifying the probable reasons from the patient’s 
prescription with the help of  STGs and literatures 
also. The DRPs was assessed for the appropriateness 
of  – drug indications, drug and dosage, probable 
drug interactions, ADR and contraindications with 
three references. Causes for DRP was assessed and 
intervened. Recommendation was communicated to the 
physician and changes made. The incidences of  DRPs 
were discussed with the diabetologist and appropriate 
new therapy was initiated for those having DRPs. The 
interview on medication review was conducted for 10 
– 15 minutes for each patient to identify the complexity 
of  the medication regimen and problems detected. The 
control group was given usual treatment.
Psychological Aspect treatment 
The intervention group was provided with psychological 
aspect treatment (PAT) at baseline and 3, 6, 9 and 
12 months by trained pharmacists, with a structured 
interview and motivational interviewing skills at both 
the study sites. The first session was conducted within 
one week of  selection of  participants for the study. 
The patient was informed on the contraindications, 
indications, side effects, administration and frequency 
of  the medicine(s). Patients were counseled in-line with 
the motivational interviewing strategies to improve their 
medication adherence. OTC medicines were also taken 
into the consideration for medication review during 
the study period. For the PAT 25 to 30 minutes were 
conducted for each patient during every two visits. For 
the control group no PAT test was performed. (Frank 
Petrak et al, 2005)
Workshop for Community Pharmacists 
Four sessions were conducted for the community 
pharmacists who were participated in this study on 
the above parameters. They were explained about the 
background of  medication review, DRP score forms 
and evaluation pattern during the sessions. The pilot 
study was conducted to minimize the variability while 
assessing DRP score and reviewing the medication 
among the trained pharmacists. The assessed review on 
medication by trained pharmacist was reassessed by a 
specialist in medication review. The trained pharmacist 
was expected to identify more DRPs in interventional 
than control group pharmacists who was not attended 
the workshop on medication review. The assessment 
was carried out similar to that of  pilot study. During 
one day workshop all the pharmacists were explained 
on motivational interviewing and decision making as 
well as communication skills. 
Outcome Measures
Primary outcome measures
At the end of  the study period researcher and coauthors 
calculated the incidences of  DRP and compared the 
primary outcome with baseline, control and intervention 
groups by using a checklist which includes common 
drug problems. Among the enrolled patients DRPs were 
assessed and documented by conducting the structured 
interview and medication review was carried out the 
study participants (pharmacists).
Medication Adherence with Therapy
The 8-item self-report Morisky Medication Adherence 
Scale (MMAS) was used to assess medication adherence. 
(Morisky. DE et al, 1986)
Secondary outcome measures
Secondary outcomes include fasting plasma glucose 
level, hypoglycaemic episodes, morbidity, adverse effects 
and total incidence of  patient visit to diabetiologist for 
consultation of  probable drug related problem during 
the study period was measured. The incidence of  clinic 
visit was obtained from the prescriptions. 
ADR causality assessment was carried out by using 
Naranjo’s scale and assessed by the coauthors. (Naranjo. 
CA, et al, 1981) All participants completed 4 validated 
questionnaires during the study period. The first 
questionnaire was given to the participants 7 days initial 
to the first counselling. The second questionnaire was 
given at 6 months; the third questionnaire was given at 
9 months and the fourth was given at 12 months. 
Sample size
The incidence of  DPRs was weighed with respect to 
primary outcome of  the medication review and patient 
counseling. From the literature review, 25% of  control 
group patients were encountered with DRPs and 
30% of  DRPs were decreased due to intervention. In 
a type 1 error of  0.05, a power of  90%, and a ratio     
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of  one between both groups of  patients, multilevel 
randomisation resulting in a loss of  power of  10%, a 
total of  800 patients was needed to show a statistically 
significant difference. 
Statistical Analysis
 Descriptive analysis was done for the demographic 
characteristics of  patients and other control variables 
both groups. Difference was tested using chi-square or 
t-tests. To test the effect of  the intervention a multilevel 
design was used. Medication event was clustered within 
patients, and patients are clustered within pharmacies. 
The primary outcome, the adherence, is the dependent 
variable. To assess the impact of  the intervention, 
multilevel linear and logistic regression analysis was 
conducted to study differences in outcome measures 
among patients of  the intervention and control groups. 
All independent variables of  importance, for example 
socio-demographic factors and medication regimen, 
are included in the model to adjust for these variables. 
Data are analysed with SigmaStat for Windows (Demo 
Version) and differences in changes among the group 
were measured with 95% confidence intervals. 
Results
Over 12 month study, participants’ average HBA1C 
reduced from 8.9% at initial visit to 7.5%, average LDL 
was reduced from 124.1 mg/dL to 109.6 mg/dL, and 
average BP was reduced from 141.5 mm Hg to 132.7 
mm Hg. During this time, the eye examination rate was 
raised from 31% to 48%, and the foot examination 
rate was raised from 35% to 50%. Only 48.25% of  
participants were satisfied diabetes care was better from 
45.5% of  participants in the highest range at baseline to 
51.30% at this level after 12 months (Table No.1).
Table No. 1: Demographic and clinical characteristic of  the patients (N = 723)







Duration of  hospital stay
Not more than7 days 515 (71.23)
8 to 14 days 157 (21.72)
More than 15 days 051 (07.05)
Duration of  type 2 diabetes mellitus
Not more than 10 years 247(34.16)
11 to 20 years 224 (30.98)
21 to 30 years 108 (14.94)
Unknown duration 070 (09.68)
Duration of  hypertension
Not more than 10 years 209 (28.91)
11 to 20 years 178 (24.62)
21 to 30 years 162 (22.41)
Unknown duration 174 (24.01)
HbA1c
Achieved target (< 6.5) 210 (24.04)
Did not achieve target (≥ 6.5) 513 (45.96)
Diabetic complications†
Diabetic retinopathy 84 (11.62)
Diabetic foot ulcer 118 (16.32)
Diabetic neuropathy 073 (10.10)
Comorbidities‡
Renal impairment 94 (13.00)
Cardiovascular disease 123 (17.01)
Dyslipidemia 104 (14.38)
Stroke 051 (07.05)
Gastrointestinal  disease 012 (1.66)
Liver impairment and Bronchial asthma 021 (2.09)
† – One patient may have more than one diabetic complication
† - One patient may have more than one comorbidity
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In the present study, the DRPs in TDM and comorbid 
patients observed are recorded in Table No. 2. The type 
of  problems experienced was typically due to errors in 
the medication adherence and compliance. Out of  the 
723 patients 6.92 % (n=50) of  the patients experienced 
adverse drug reactions that were non allergic in nature, 
26.96 % (n=193) of  them showed problems associated 
with choice of  the drug, 16.45% of  the patients 
developed dosing related problems, 14.94% (n=108) 
of  the patients experienced drug use problems as they 
did not administer the drugs at all, 13.28 % (n=96) of  
them showed potential drug interactions. 31.53% of  the 
reported other problems like patient dissatisfied with 
therapy despite taking drug(s) correctly (3.32%) and 
insufficient awareness of  health and diseases (26.28%) 
and 1.94% experienced therapy failure.
Table No. 2: Drug related problems in T2DM patients with hypertension (n = 723)
Code Problems* No. of  problem 
(%)
P1 Adverse reactions 45 (6.22)
P1.1 Side effects suffered (non-allergic) 50 (6.92)
P2 Drug choice problems 167 (23.10)
P2.1 Inappropriate drug (not most appropriate for 
indication)
64 (8.85)
P2.2 Inappropriate drug form (not most appropriate for 
indication)
11 (1.52)
P2.3 Inappropriate duplication of  therapeutic group or 
active ingredient
18 (2.49)
P2.4 Contraindication for drug 59 (8.16)
P2.5 No clear indication for drug use 9 (1.24)
P2.6 No drug but clear indication 32 (4.43)
P3 Dosing problems 123 (17.01)
P3.1 Drug dose too low or dosage regime not frequent 
enough
8 (1.11)
P3.2 Drug dose too high or dosage regime too frequent 88 (12.17)
P3.3 Duration of  treatment too short 10 (1.38)
P3.4 Duration of  treatment too long 13 (1.80)
P4 Drug use problems 99 (13.69)
P4.1 Drug not taken/administered at all 108 (14.94)
P5 Interactions 133 (18.40)
P5.1 Potential interaction 96 (13.28)
P6 Others 202 (27.94)
P6.1 Patient dissatisfied with therapy despite taking drug(s) 
correctly
24 (3.32)
P6.2 Insufficient awareness of  health and diseases 
(possibly leading  to future problems)
190 (26.28)
P6.4 Therapy failure (reason unknown) 14 (1.94)
*Only problems that have a frequency of  more than one were included.
The causes of  the above mentioned DRPs in T2DM with 
hypertension were evident in 696 patients as shown in 
Table No. 3. The major causes assessed were due to drug 
and dose selection 47.55% (n=331), drug use process 
such as in appropriate timing of  administration, drug 
under administered and patient unable to use the drug 
or dosage form as directed. The second major cause of  
the DRPs in these patients were patient/ psychological 
associated evident in 39.65% (n=276) of  the patients, 
followed by drug use process in 14.65% (n=102). In 
8.47% (n=59) it was due to lack of  proper instructions 
for use of  drugs, unawareness of  the reason for drug 
treatment and unable to understand the local language. 
6.6% (n=46) due to logistic issues such as prescribed 
drug not available (anymore) and prescribing errors. 
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Table No. 3: Causes of  DRPs in T2DM patients with hypertension (n = 696)
Code Causes* No. of  problem (%)
C1 Drug/ Dose selection 348 (50.0)
C1.1 Inappropriate drug selection 140 (20.12)
C1.2 Inappropriate dosage selection 118 (16.95)
C1.5 Synergistic/preventive drug required and not given 35 (5.03)
C1.8 Manifest side effect, no other cause 38 (5.46)
C2 Drug use process 93 (13.62)
C2.1 Inappropriate timing of  administration and/or dosing 
intervals
18 (2.59)
C2.2 Drug underused/under-administered 73 (10.49)
C2.6 Patient unable to use drug/form  as directed 11 (1.58)
C3 Information 51 (7.33)
C3.1 Instructions for use/taking not known 21 (3.02)
C3.2 Patient unaware of  reason for drug treatment 19 (2.73)
C3.4 Patient unable to understand local language 19 (2.73)
C4 Patient/Psychological 242 (34.77)
C4.1 Patient forgets to use/take drug 31 (4.54)
C4.2 Patient has concerns with drugs 14 (2.01)
C4.3 Patient suspects side-effect 21 (3.02)
C4.5 Patient unwilling to bother physician 13 (1.88)
C4.7 Patient unwilling to adapt life-style 68 (9.77)
C4.8 Burden of  therapy 94 (13.50)
C4.9 Treatment not in line with health beliefs 35 (5.03)
C5 Logistic 14 (2.01)
C5.1 Prescribed drug not available (anymore) 33 (4.74)
C5.2 Prescribing error (only in case of  slip of  the pen) 13 (1.87)
*Only causes that have frequency of  more than one were included.
From Table No. 4, the factors causing the DRPs in 
T2DM patients with hypertension are the age of  the 
patient, intake of  number of  medicines, duration 
of  hospital stay and other comorbid conditions like 
microvascular complications, cardiovascular events, 
renal  as well as liver impairment and hyperlipidaemia. 
In the present study, we have compared the 
factors and occurrence of  DRPs like adverse drug 
reaction, drug choice problems, dosing problems 
Adverse drug reactions: As summarized in table no: 4, 
among the 375 patients; 51 of  them had experienced 
ADRs whereas 324 of  them did not. Among the group 
of  patients who had experienced them, about 45.1% 
of  them were elderly patients and 55.90% of  them 
were non elderly patients. On the other hand, among 
the 324 who were not affected by any ADRs, 41.36% 
and 58.64% were elderly and non elderly respectively. 
Depending upon the second factor i.e., polypharmacy, 
89.39% of  them were taking many medicines for 
different conditions experienced ADRs while the rest 
19.61% were not taking polypharmacy. Whereas out of  
those 324 who did not have any ADRs, among them 
76.6% were taking polypharmacy while 23.4% of  the 
patients were not. Considering the duration of  hospital 
stay as one of  the factor for occurrence of  ADRs, 
60.78% of  the patients had them in the duration of  
≤ 1 week, while 39.22% of  them for the duration of  
> 1 week. In contrast with this, the ones who had not 
experienced ADRs, for duration of  ≤1 week and > 1 
week were 62.96% and 37.04% respectively. The patients 
living with other complications like microvascular 
complications, cardiovascular events, renal impairment, 
liver impairment and hyperlipidaemia and experienced 
ADRs were 58.82%, 40.06%, 54.90%, 7.84% and 
41.18% respectively and the ones without these above 
mentioned complications but yet ADR occurrence was 
reported were 41.18%, 52.94%, 45.10%, 92.16% and 
58.82% respectively. Among the 324 who had no ADRs 
but living with the above mentioned complications 
were 54.63%, 55.86%, 58.02%, 8.02% and 29.32% 
respectively, while the patients without the ADRs and 
also without the above complications were 45.37%, 
44.14%, 41.98%, 91.98% and 70.68% respectively.
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Table No. 4: Comparison between factors and occurrence of  adverse reactions, drug choice 
problems, and dosing problems (375)
Factors Adverse reactions (n = 375) 
n (%)
Drug choice problem (n = 375) n 
(%)
Dosing problem (n = 375) n 
(%)
Yes (n = 
51)
No (n = 
324)
P-value Yes ( n = 
149)
No (n = 
226)
P-value Yes (n = 
118)




Yes 23 (45.10) 134 
(41.36)
> 0.9a 62 (41.61) 161 
(71.24)
< 0.01a* 73 (61.86) 148 
(57.59)
0.5a
No 28 (55.90) 190 
(58.64)
87 (58.39) 65 (28.76) 45 (38.14) 109 
(42.41)
Polypharmacy
Yes 41 (89.39) 134 (76.6) > 0.9a 120 (80.54) 173 
(76.45)
0.05a 81 (68.64) 201 
(78.21)
0.1a
No 10 (19.61) 41 (23.4) 29 (19.46) 53 (23.45) 37 (31.36) 56 (21.79)
Duration of  hospital stay
≤ 1 
week
31 (60.78) 204 
(62.96)
0.5a 95 (63.74) 188 
(83.19)





20 (39.22) 120 
(37.04)
54 (36.26) 38 (16.81) 28 (23.73) 64 (24.92)
Microvascular complication
Yes 30 (58.82) 177 
(54.63)





No 21 (41.18) 147 
(45.37)
44 (29.53) 95 (42.04) 18 (15.25) 103 
(40.08)
Cardiovascular events
Yes 24 (40.06) 181 
(55.86)
0.1b 97 (65.10) 138 
(61.06)
0.05a 77 (65.24) 158 
(61.48)
0.5a
No 27 (52.94) 143 
(44.14)
52 (34.90) 88 (38.93) 41 (34.74) 99 (38.52)
Renal impairment
Yes 28 (54.90) 188 
(58.02)
> 0.9a 94 (63.09) 85 (37.61) 0.05a* 80 (67.80) 126 
(40.03)
0.05a*
No 23 (45.10) 136 
(41.98)
55 (36.91) 141 
(62.39)
38 (32.20) 131 
(50.97)
Liver impairment
Yes 4 (7.84) 26 (8.02) > 0.9b 16 (10.74) 21 (9.29) 0.50a 18 (15.25) 16 (6.22) 0.50a
No 47 (92.16) 298 
(91.98)







Yes 21 (41.18) 95 (29.32) 0.5a 41 (27.52) 88 (38.94) 0.05a* 35 (29.66) 93 (36.19) 0.50a
No 30 (58.82) 229 
(70.68)
108 (72.48) 138 
(61.06)
83 (70.34) 164 
(63.81)
a Computed using Continuity Correction; b  Computed  using Fisher’s Exact Test; 
* Statistically significant (p < 0.05).
Drug Choice Problems: Among the total 375 patients, 
149 of  them experienced DCPs while 226 did not show 
any kind of  DCPs. Among the 149 of  the patients in 
whom DCPs occurred, 41.61% were elderly and the rest 
were non elderly, 58.39%. 80.54% of  them were taking 
polypharmacy while 19.46% were not. It was evident 
in the patients whose duration of  stay in the hospital 
was for ≤1 week and > 1 week by 63.74% and 36.26 % 
respectively. The occurrence of  DCPs in patients with 
microvascular complications, cardiovascular events, 
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renal impairment, liver impairment and hyperlipidaemia 
were 70.47%, 65.10%, 63.09%, 10.74% and 27.52% 
respectively, whereas in the patients without the 
above complications but still the DCPs were evident 
were 29.53%, 34.90%, 36.91%, 89.26% and 72.48% 
respectively. On the other hand, among the 226 patients 
who did not experience DCPs, 71.24% were elderly and 
28.76% were non elderly patients. 76.45% were taking 
polypharmacy while 23.45% were not. About 83.19% of  
the patients who were hospitalized for </= 1 week and 
16.81% for > 1 week had not experienced any kind of  
DCPs. The patients living with the other complications 
like microvascular problems, cardiovascular events, 
renal and liver impairment and hyperlipidaemia but 
no DCPs were evident were 57.96%, 61.06%, 37.61%, 
9.29%, 38.94% respectively and the rest of  them had no 
complications and no DCPs.
 
Dosing problems: Among the sample size of  375, 118 
of  them experienced dosing problems (DPs) whereas 
257 of  them did not. Among the ones who experienced 
DPs (n=118), 61.86% are elderly patients and remaining 
38.14% of  them are non-elderly patients. About 68.64% 
of  them take Polypharmacy and the rest 31.36% of  
them do not.76.7% of  the patients reported DPs within 
≤1 week of  hospital stay while 23.73% of  the patients 
within >1 week of  hospital stay. The patients in whom 
the DPs were evident and who were living with other 
complications like microvascular, cardiovascular events, 
renal impairment, liver impairment and hyperlipidaemia 
were 84.74%, 65.24%, 67.80%, 15.25% and 29.66% 
respectively, whereas the remaining experienced DPs 
but did not have any of  the mentioned complications. 
Among the ones, in whom DPs were not seen 
(n=257), 57.59% were elderly patients while the rest 
42.41% were non elderly patients. 78.21% were taking 
Polypharmacy but 21.79% were not. In ≤ 1 week or 
> 1 week of  hospitalization, 75.08% and 24.92% 
respectively, the patients did not experience any DPs. 
With microvascular, cardiovascular, renal, liver and 
hyperlipidaemia complications of  59.92%, 61.48%, 
40.03%, 6.22% and 36.19% respectively, the patients 
did not experience DPs whereas the rest of  them had 
no complications and also no DPs.
Drug Use Problems: Among the 374 sample size, the 
patients who experienced DUPs were 97 and who did 
not have DUPs were 227. In both the scenarios, the 
majority of  the patients affected were the non-elderly 
patients, 68.04% and 57.72% respectively but among the 
elderly patients, 31.96% and 42.28% respectively. The 
patients who are experiencing DUPs while taking poly 
pharmacy are 68.0%, while not taking polypharmacy are 
32.0% whereas, the ones not have DUPs while taking 
and not taking polypharmacy are  70.67% and 29.33%. 
The DUPs were high in the patients whose duration of  
stay in hospital is ≤ 1 week, 75.26% compared to the 
ones with hospitalization for > 1 week, 24.74%. The 
patients with the complications like the microvascular, 
cardiovascular, renal impairment, liver impairment 
and hyperlipidaemia, in whom the DUPs were evident 
were 64.95%, 53.61%, 49.48%, 10.31% and 40.21% 
respectively.
 
Drug interactions: The patients who experienced drug 
interactions were 125 and who did not were 199. In this 
type of  DRP, the majority of  patients affected were from 
the elderly group of  patients i.e., 61.60% and 58.02% 
respectively. The patients in whom, the drug interactions 
were evident while taking and not taking polypharmacy 
are 94.4% and 69.75% respectively. About 75.20% of  
them showed drug interactions in ≤ 1 week of  duration 
of  stay in hospital and 24.80% within > 1 week of  
hospital stay. The drug interaction were reported in 
patients living with microvascular, cardiovascular, renal, 
liver and hyperlipidaemia complications by 67.20%, 
82.40%, 58.40%, 1.60% and 62.60% respectively.
 
Other Problems: Overall 187 of  the patients had 
experienced other DRPs while 137 of  the patients did 
not. Among them the percentile of  elderly patients is 
61.50% and 56.93% and that of  non-elderly is 38.50% 
and 43.06% respectively. In the patients who were 
taking polypharmacy, the evidence of  other DRPs were 
high 78.61 % when compared to those who were not 
taking polypharmacy, 21.39%. 72.19% of  them showed 
other problems in duration of  ≤1 week of  hospital stay 
and 27.81% in duration of  > 1 week hospitalization. 
The other DRPs in patients with microvascular, 
cardiovascular, renal, liver and hyperlipidaemia 
complications are evident with the percentile of  72.73%, 
65.78%, 52.94%, 6.42% and 69.89% respectively.
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Table No. 5: Comparison between factors and occurrence of  drug use problems, drug 
interactions, and other problems (375)
Factors Drug use problems Drug interactions Other problems
Yes (n = 
97)
No (n = 
227)
p-value Yes (n = 
125)
No (n = 
324
p-value Yes (n = 
187)




Yes 31 (31.96) 96 (42.28) 0.2a 77 (61.60) 188 
(58.02)
0.9a 115 (61.50) 78 (56.93) 0.8a
No 66 (68.04) 131 
(57.72)
48 (38.40) 136 
(41.98)
72 (38.50) 59 (43.06)
Polypharmacy
Yes 69 (68.0) 160 
(70.67)
0.2a 118 (94.40) 226 
(69.75)
0.001a* 147 (78.61) 109 
(79.56)
> 0.9a
No 28 (32.0) 67 (29.33) 7 (5.6) 98 (30.25) 40 (21.39) 28 (20.44)
Duration of  hospital stay
≤ 1 
week
73 (75.26) 154 
(67.90)
0.8a 94 (75.20) 233 
(71.91)





24 (24.74) 73 (32.10) 31 (24.80) 91 (28.09) 52 (27.81) 34 (24.82)
Microvascular complications
Yes 63 (64.95) 118 
(60.49)
> 0.9a 84 (67.20) 208 
(64.20)
0.6a 136 (72.73) 79 (57.66) 0.2a
No 34 (35.05) 109 
(39.51)
41 (32.80) 116 
(35.80)
51 (27.27) 58 (42.34)
Cardiovascular disease
Yes 52 (53.61) 132 
(58.33)




123 (65.78) 75 (54.74) 0.3a
No 45 (46.39) 95 (41.67) 22 (17.60) 188 
(58.02)
64 (34.22) 62 (45.26)
Renal impairment
Yes 48 (49.48) 97 (39.51) 0.4a 73 (58.40) 151 
(46.40)
0.8a 99 (52.94) 71 (51.82) > 0.9a
No 49 (50.52) 130 
(60.49)
52 (41.60) 173 
(53.40)
88 (47.06) 66 (48.18)
Liver impairement
Yes 10 (10.31) 12 (5.25) 0.5b 2 (1.60) 21 (6.48) 0.02b* 12 (6.42) 8 (5.84) > 0.9a
No 87 (89.69) 215 
(94.75)
123 (98.40) 303 
(93.52)
175 (93.58) 129 
(94.16)
Hyperlipidemia
Yes 39 (40.21) 81 (35.80) 0.2a 78 (62.40) 185 
(57.10)
0.9a 112 (59.89) 78 (56.93) 0.8a
No 58 (59.79) 146 
(64.20)
47 (37.60) 139 
(42.90)
75 (40.11) 59 (43.06)
a Computed using Continuity Correction; b  Computed  using Fisher’s Exact Test; 
* Statistically significant (p < 0.05).
Discussion
The population of  India is over 1000 million (1260 
million in 2012). According to the International 
Diabetes Federation, 61.3 million people in India had 
diabetes in 2011. That figure is projected to rise to 
101.2 million by 2030.The prevalence rate of  diabetes 
in the urban areas of  India is thought to be 9 per cent 
and 3 per cent approximately in the rural areas, of  the 
total population. This statistics helps to give an idea 
of  the scale of  the problem. (Population Reference 
Bureau, 2012 and Global Diabetes community). The 
sanofi-aventis India SITE study (Screening India’s Twin     
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Epidemic), rolled out during 2009/ 2010, was a cross-
sectional epidemiological study of  16,000 patients from 
800 centers in Maharashtra, New Delhi, Tamil Nadu, 
Andhra Pradesh, West Bengal, Karnataka, Gujarat, and 
Madhya Pradesh. About 60 percent of  the surveyed 
population suffered from diabetes, hypertension, or 
both, and 70 percent of  the patients had uncontrolled 
diabetes. [Sanofi-aventis’ India SITE study shows 62% 
of  diabetic population in New Delhi has ‘uncontrolled’ 
diabetes. Mumbai, India: Aventis Pharma Limited; 
2010.]
 
According to the citations in the Population Reference 
Bureau: 2012 World Population Data Sheet, the non 
communicable diseases (NCDs), such as cardiovascular 
diseases, cancers, diabetes, and chronic lung diseases, 
are the leading causes of  death in all regions except 
sub-Saharan Africa. In 2008, almost two-thirds of  all 
the deaths globally were due to NCDs. Nearly 4 out 
of  5 deaths from NCDs occurred in low- and middle-
income countries. While the number of  people suffering 
and dying from NCDs will continue to increase around 
the world over the next several decades, the greatest 
increases are expected in low-income countries. In 
South Asia, deaths due to NCDs are projected to 
increase from half  to almost three-quarters of  all deaths 
between 2008 and 2030. [Population Reference Bureau; 
2012 World Population Data Sheet. Washington DC, 
USA: USAID; 2012] 
 
DRPs the most important aspect in the pharmaceutical 
care. The terms such as medication errors are often 
used to describe this concept, but it is different from the 
actual understanding of  DRPs. The medication errors 
refer to the mistakes in the process that could lead to 
problems in an individual whereas, DRPs  can occur 
when prescribing, dispensing or taking/ administering 
medicines. There are several classifications framed to 
understand the factors, causes and problems arising 
due to drugs but in this study PCNE classification 
for DRP is used. A  DRP is an event or circumstance 
involving drug therapy that actually or potentially 
interferes with desired health outcomes. (Bob W. van 
Roozendaal and Ines Krass, 2009)
This study was conducted on 723 patients, out of  which 
389 (50.8%) were male and 334 (49.2%) were female 
patients. To reduce the drug related problems the 
causes and factors should be known. According to the 
PCNE classification, 6 major domains of  Drug related 
problems in this study such as adverse drug reactions, 
drug choice problem, dosing problem, drug use 
problem, drug interactions and others were recorded.
Adverse Reactions
The WHO defines adverse drug reaction as “a response 
to a drug that is noxious and unintended and occurs 
at doses normally used in man for the prophylaxis, 
diagnosis or therapy of  disease, or for modification 
of  physiological function”. Adverse drug reaction 
are classified as side effects that are allergic, non 
allergic or toxic. 50 patients (6.92%) reported having 
experienced at least one episode of  reaction of  any 
kind. In contrast with the similar studies conducted in 2 
different countries, Australia based study 43 out of  148 
patients (6.3%) and in Malaysia based study 25 out of  
387 (6.5%) patients experienced these type of  reactions, 
assuming that same category of  anti diabetic drugs and 
anti hypertensive drugs were given. This kind of  drug 
related problems can be an outcome of  prescribing 
error, but unexpected ADRs may also occur at normal 
dosages of  a well selected drug.
 
Drug Choice Problems
Patient gets or is going to get a wrong (or no drug) 
drug for their disease and/ or condition. This is usually 
a prescribing error. These errors commonly occur 
due inappropriate drug selection and 140 cases were 
reported for the same. This category of  problem was 
recorded 193 times. 64 out of  193 drug choice problems 
were due to the administration of  the drugs that were 
inappropriate for the patient’s condition and 59 of  193 
were due to contraindication of  the drug, followed by 
others. In some patients, synergistic or preventive drug 
was required but the patients did not receive, reported 
cases were 35.The Drug choice problem contributes to 
26.69% of  the errors. In the Australia based study, this 
category of  DRP contributes 30.2% of  all DRPs and 
the most precipitating factor is no drug prescribed even 
when the indication of  illness is clear i.e., 182 of  206 
(26.7%). Whereas in Malaysia, this category of  DRP 
contributes 22.5% of  the rest DRPs, and the leading 
factors are inappropriate drug administration followed 
by contraindications of  the drug.
 
Dosing Problems
This category of  DRP occurs when the patient gets the 
right drug, but in insufficient amount than required. 
This can be a prescribing error or a drug use error. This 
occurs due to inappropriate dosage selection for which 
118 reports were recorded. Dosing errors are recorded 
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119 times in this study constituting for 16.45% of  
all the DRPs. 88 out of  119 of  this DRP are due to 
high dose or dosage regime too frequent. This is the 
leading contributing factor for the dosing related drug 
problem in the studies based in Australia (27 out of  
40) and Malaysia (44 out of  62). This is a very serious 
factor and through monitoring is required during the 
period of  therapy. Otherwise, the dosing related drug 
problems constitute to 16% and 5.9% of  the overall 
DRPs in Malaysia and Australia respectively.
Drug Use Problems
These kinds of  DRPs arise when the patient administers 
the wrong drug or does not take any drug. This can be 
drug use error, administration error and/or filling error 
in the pharmacy. Proper patient counseling or educating 
the patient about the disease and the need for treatment 
can help overcome this problem of  medication 
adherence and discouraging the idea of  self  medication 
and over the counter medication can be effective in 
significantly reducing the risk of  wrong medication. 
Here the risk of  potential non adherence was the major 
factor, 108 cases were recorded contributing to 14.94% 
of  all the DRPs. The causes of  DRP due to drug use 
(n=102) were inappropriate timing of  administration 
and dosing intervals 18 out of  102, drug unused or 
under-administered were 73 0f  102 and 11 out of  102 
were because patients were unable to use the medication 
as directed.12.9% and 3.8% was seen for potential non 
adherence in Malaysia and Australia respectively.
Potential Interactions 
The potential drug-drug or drug-food interaction is a 
form of  prescribing or drug-use error.96 cases were 
reported in the study. The interactions identified were 
mostly based on established literature and evidence 
recorded and complied in authenticated resources. 
The drug interactions contribute to about 13.28% of  
all the DRPs, where as in Australia and Malaysia they 




The other problems reported in this study were 
228, 31.53% of  all the DRPs recorded. On further 
interviewing and assessing the data of  those 288 cases, 
it was found that 190 of  228 had inadequate awareness 
about the health and disease, that could precipitate and 
cause long term effects, 24 of  228 were not satisfied 
with the therapy without any error of  non adherence 
and 14 of  228 experienced failure of  the therapy, 
however the reason couldn’t be noticed. By contrast, 
the leading cause reported in Malaysia was inadequate 
awareness but in Australia it was therapy failure.
Conclusion: 
The findings of  the study have less significant 
improvement in their primary and secondary outcomes. 
It may be concluded, therefore, that the intervention 
pharmacists showed no demonstrable influence on 
any of  the intermediate health outcomes relating to 
metabolic control or on therapeutic adherence in T2DM 
that was significantly different from that exerted by the 
control cohort of  pharmacists.
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